Home > Core technology > Gene-Modified Stem Cell Therapy for Monogenic Inherited Diseases
Autologous hematopoietic stem cells are collected and ex vivo modified via viral vector-mediated delivery of functional genes, or corrected for pathogenic mutations using gene-editing tools. Following myeloablative conditioning, the corrected stem cells are reinfused back into the patient, allowing the corrected stem cells to engraft in the bone marrow and continuously produce progeny cells with normal function, thereby correcting the genetic defect at its root.